体軸型脊椎関節炎に対するビメキズマブの有効性と安全性: 2つのフェーズ3無作為化対照試験結果
Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595
Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.
February 2023
January 2023
活動性強直性脊椎炎患者におけるbimekizumabの安全性と 有効性: フェーズIIb無作為化対照試験とそのオープンラベル延長試験 からの3年結果
Arthritis Rheumatol. 2022;74:1943–58
In this open-label extension study of BE AGILE, the safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The objective was to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.
Keywords:
August 2022
活動性強直性脊椎炎患者におけるビメキズマブの安全性と有効性: フェーズ2b 無作為化対照試験とそのオープンラベル試験の3年結果
Arthritis Rheumatol 2022 doi: 10.1002/art.42282
Bimekizumab is associated with sustained, long-term efficacy in r-axSpA patinets across three years of treatment. In coming to this conclusion, investigators sought to assess the long-term safety, tolerability, and efficacy of bimekizumab in active r-axSpA.